A prevention bundle reduced inflammation, infections and hospitalizations among nursing home residents with peripherally ...
According to “Cancer incidence estimates for 2022 & projection for 2025” published in the Indian Journal of Medical Research ...
In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with significantly longer disease-free survival than placebo (24 months: 77% vs. 68%; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback